LEIDEN, the Netherlands and CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced
… ProQR Announces Expert Perspectives Call on LCA10 and … & CAMBRIDGE, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … presentation by Aniz Girach, MD, Chief Medical Officer of ProQR Therapeutics. Dr. Girach will then discuss the …
… ProQR Announces Annual General Meeting of Shareholders and … & CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a …
… ProQR Announces Results for the Fourth Quarter and Full Year … and full year 2015. “2015 was a year of execution for ProQR. From the inception of ProQR in 2012, we had been … study is also assessing sweat chloride, weight gain, CFQ-R Respiratory Symptom Score and lung function, measured by …
… ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 LEIDEN, Netherlands & CAMBRIDGE, … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …
… ProQR Supports Rare Disease Day 2018 and Honors Henri A. … the legacy of the late Henri A. Termeer, co-founder of ProQR, being held on the same day in Boston, MA. Henri … Genzyme and a visionary and pioneer for rare diseases, was ProQR’s co-founder in 2012 and vice chairman of the …